Skip to main content Accessibility help
×
Home

Contents:

Information:

  • Access
  • Cited by 1

Actions:

      • Send article to Kindle

        To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Comment on a meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease
        Available formats
        ×

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Comment on a meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease
        Available formats
        ×

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Comment on a meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease
        Available formats
        ×
Export citation

Dear Editor,

We read with great interest the meta-analysis by Yang et al 1 comparing re-treatment efficacy of glucocorticosteroids or intravenous immunoglobulin for patients with immunoglobulin-resistant Kawasaki disease. The results from this analysis of four cohort studies involving 52 patients treated with second intravenous immunoglobulin and 75 patients treated with glucocorticosteroid suggested that glucocorticosteroids are more effective in controlling body temperature compared with intravenous immunoglobulin and that there was no difference in the prevention of coronary artery lesions between groups.

The aim of their study was to determine the optimal drug therapy for intravenous immunoglobulin-resistant Kawasaki disease; however, they only evaluated the effects of a second intravenous immunoglobulin compared with glucocorticoids as a clinical treatment for intravenous immunoglobulin-resistant Kawasaki disease. There are only two agents involved in this meta-analysis, and some other agents may also have the efficacy to improve the process of immunoglobulin-resistant Kawasaki disease, such as infliximab.

For reasons that are unclear, among the four selected manuscripts, two belong to the same author, 2 , 3 and each date is derived from the same trial of different stages. Such problems weaken the validity of the meta-analysis by Yang et al.

Nevertheless, we extol Yang et al on their effort, and studies such as this meta-analysis are necessary to gain optimal re-treatment methods, which remain controversial for immunoglobulin-resistant patients. Such studies should be conducted in a way that includes broad agents and must avoid errors cautiously.

Thank you very much!

Best regards to you!

Yuan-han Qin

References

1. Yang, X, Liu, G, Huang, Y, Chen, S, Du, J, Jin, H. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young 2015; 25: 11821190.
2. Miura, M, Ohki, H, Yoshiba, S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005; 90: 10961097.
3. Miura, M, Kohno, K, Ohki, H, Yoshiba, S, Sugaya, A, Satoh, M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 2008; 167: 11191123.